Lester Robertson is an Oncology physician. OpenAlex indexes 14 publications with 366 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
225 Candler Dr
Savannah, GA 314056023
Telephone
912-354-6187Provider last certified this registry record 18 Jun 2024.
Industry payments
73 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202513 payments
- Merck Sharp & Dohme LLCProgram year202510 payments
- Regeneron Healthcare Solutions, Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
57.4%RANK Ligand Inhibitor57.4%Denosumab100%Part B, office-administered≥20 patientsCancer & immunology
14.7%Aromatase Inhibitor5.8%Anastrozole76%Exemestane15%Letrozole9%Part D<11 patientsThalidomide Analog2.2%Lenalidomide53%Pomalyst47%Part D<11 patients+ 7 more classes in this area
Sensory organs
12.1%Corticosteroid12.1%Dexamethasone sodium phosphate93%Dexamethasone7%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sequential Cis-Platinum and Fludarabine with or without Arabinosyl Cytosine in Patients Failing Prior Fludarabine Therapy for Chronic Lymphocytic Leukemia: A Phase II Study
Leukemia & lymphoma/Leukemia and lymphoma
1999 - Fludarabine phosphate in lymphoma: an important new therapeutic agent
Cancer treatment and research
1997 - Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
PubMed
1996 - The Expanding Role of Fludarabine in Hematologic Malignancies
Leukemia & lymphoma/Leukemia and lymphoma
1994
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”